BHC

Bausch Health Companies Inc.

Healthcare · $2.3B market cap

Verdict

Share price

$5.80

close of Oct 3, 2026

Fair value

$15.85

Sticker Price

Payback Price

$6.34

buy price

On Sale

BHC is On Sale: at $5.80 it trades 9% below its buy price (Payback Price) of $6.34 and 63% below its fair value of $15.85. Business quality is limited: none of the 5 key numbers clears the 10% bar.

How we valued it

Free Cash Flow Growth. Reported earnings are shrinking, but free cash flow keeps growing, so we value it on cash flow.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth-0.8% a year✗
Equity per share growth-1.0% a year✗
Sales growth8.8% a year✗
Free cash flow growth8.1% a year✗
Return on invested capital1.4%✗

Follow BHC

Get notified when it reaches its buy price of $6.34. Free.

Create a free account

Superinvestors

None of the investors we track holds BHC right now. In Q1 2026, 2 sold out. Who we track

Moves in Q1 2026

Sold out: Howard Marks, Daniel Loeb

Insider activity

Since Jun 30, 2026: no open-market purchases, 1 sale worth $259K and 6 other filings (stock awards, tax withholding and similar). Why purchases matter

Sales

Other filings

About Bausch Health Companies Inc.

Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb…

Drug Manufacturers - Specialty & Generic

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works